Switching to faricimab from aflibercept during maintenance treatment period for age-related macular degeneration [PDF]
Scientific ReportsTo compare the short-term treatment outcomes of aflibercept and faricimab for neovascular age-related macular degeneration (nAMD) during the maintenance treatment period, we included 82 eyes of 74 patients who switched from aflibercept to faricimab ...
Misa Masaoka, Kenji Yamashiro
doaj +2 more sources
Quantitative analysis of vitreous changes in intraocular inflammation following faricimab treatment in a real world setting [PDF]
International Journal of Retina and VitreousBackground To analyze the incidence, and clinical characteristics of intraocular inflammation (IOI) associated with faricimab in a tertiary center in Austria.
Clemens Thürridl +6 more
doaj +2 more sources
Efficacy of faricimab for recalcitrant multifactorial cystoid macular edema [PDF]
American Journal of Ophthalmology Case ReportsPurpose: More information is emerging on faricimab-svoa (faricimab) used for etiologies beyond wet age-related macular degeneration (AMD) and diabetic macular edema (DME), including ongoing trials for use in macular edema following retinal vein occlusion
Justin Hanson +3 more
doaj +2 more sources
Faricimab at 6 and 12 mg reduces pigment epithelium detachment in treatment-resistant macular neovascularization: an OCT and AI analysis [PDF]
Scientific ReportsMacular neovascularization (MNV) in age-related macular degeneration (AMD) remains a therapeutic challenge, especially in eyes resistant to conventional anti-VEGF therapy.
Ines D. Nagel +10 more
doaj +2 more sources
Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US [PDF]
Ophthalmology and TherapyIntroduction The aim of this study was to compare the estimated direct and indirect costs with aflibercept 8 mg and faricimab in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) over 5 years.
Andreas Kuznik +5 more
doaj +2 more sources
Real world outcomes of faricimab in treatment resistant neovascular age-related macular degeneration among Asian patients [PDF]
Scientific ReportsTo describe the real-world efficacy and safety outcome measurements of faricimab use in treatment-resistant neovascular age-related macular degeneration (nAMD) in a cohort of Asian patients.
Elvine Zhong Oen Neo +17 more
doaj +2 more sources
Real-world outcomes of faricimab in treating diabetic macular edema up to two years [PDF]
Indian Journal of OphthalmologyPurpose: To evaluate real-world outcomes of faricimab in treating diabetic macular edema (DMO) in treatment-naive and treatment-switch patients. Design: Retrospective audit.
Tanvi Khetan +4 more
doaj +2 more sources
One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report [PDF]
Ophthalmology and TherapyIntroduction This study evaluates the efficacy and safety of faricimab in a real-world cohort of treatment-naïve patients with neovascular age-related macular degeneration (nAMD).
Anne Tillmann +21 more
doaj +2 more sources
Occlusive retinal vasculitis associated with intravitreal Faricimab injections
Journal of Ophthalmic Inflammation and InfectionPurpose We describe a case of occlusive vasculitis associated with intravitreal Faricimab (Vabysmo) injections. Methods A retrospective case report. Results A 52-year old man treated with monthly Faricimab injections for diabetic macula oedema presented ...
Felix F. Reichel +5 more
doaj +4 more sources
Case Reports in Ophthalmology, 2023 This case report describes a 78-year-old patient who developed a tear of the retinal pigment epithelium (RPE) during faricimab (Vabysmo®) therapy. After three consecutive intravitreal aflibercept (Eylea®) injections with persistent disease activity ...
Christoph R Clemens +3 more
doaj +1 more source